Sze HC - Search Results

1

Management of advanced prostate cancer in Hong Kong: Insights from an APCCC-Derived survey.

Poon DM, Ma WK, Chan TW, Ho FK, Ho LY, Leung AK, Leung SY, Sze HC, Kwong PW, Chan ES. Poon DM, et al. Among authors: sze hc. Asia Pac J Clin Oncol. 2019 Oct;15 Suppl 6:8-13. doi: 10.1111/ajco.13247. Epub 2019 Oct 23. Asia Pac J Clin Oncol. 2019. PMID: 31642191

2

Consensus statements on the management of metastatic renal cell carcinoma from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology 2019.

Poon DM, Chan CK, Chan K, Chu WH, Kwong PW, Lam W, Law KS, Lee EK, Liu PL, Sze HC, Wong JH, Chan ES. Poon DM, et al. Among authors: sze hc. Asia Pac J Clin Oncol. 2021 Apr;17 Suppl 3:27-38. doi: 10.1111/ajco.13581. Asia Pac J Clin Oncol. 2021. PMID: 33860644

3

Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer.

Poon DMC, Chan K, Chan T, Cheung FY, Lam D, Lam M, Law KS, Lee C, Lee EKC, Leung A, Sze H, Tong CC, Wong KCW, Kwong P. Poon DMC, et al. Cancers (Basel). 2022 Jan 14;14(2):407. doi: 10.3390/cancers14020407. Cancers (Basel). 2022. PMID: 35053569 Free PMC article. Review.

4

Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.

Poon DM, Chan K, Lee SH, Chan TW, Sze H, Lee EK, Lam D, Chan MF. Poon DM, et al. BMC Urol. 2016 Mar 22;16:12. doi: 10.1186/s12894-016-0132-z. BMC Urol. 2016. PMID: 27001043 Free PMC article.

5

A tale of two cities in China: Hong Kong and Shenzhen.

Lee AW, Sze H, Lam KO, Chen X. Lee AW, et al. Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):704-8. doi: 10.1016/j.ijrobp.2013.12.053. Int J Radiat Oncol Biol Phys. 2014. PMID: 24969788 No abstract available.

6

Trends and patterns of breast conservation treatment in Hong Kong: 1994-2007.

Yau TK, Soong IS, Sze H, Choi CW, Yeung MW, Ng WT, Lee AW. Yau TK, et al. Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):98-103. doi: 10.1016/j.ijrobp.2008.07.066. Epub 2008 Dec 26. Int J Radiat Oncol Biol Phys. 2009. PMID: 19101091

7

Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study.

Poon DMC, Chan K, Lee SH, Chan TW, Sze H, Lee EKC, Lam D, Chan MFT; Hong Kong Society of Uro-Oncology (HKSUO). Poon DMC, et al. Prostate Int. 2018 Mar;6(1):24-30. doi: 10.1016/j.prnil.2017.08.001. Epub 2017 Aug 18. Prostate Int. 2018. PMID: 29556486 Free PMC article.

8

HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays.

Yau TK, Sze H, Soong IS, Hioe F, Khoo US, Lee AW. Yau TK, et al. Hong Kong Med J. 2008 Apr;14(2):130-5. Hong Kong Med J. 2008. PMID: 18382020 Free article.

9

Should young age be a contra-indication to breast conservation treatment in Chinese women? Twelve-year experience from a public cancer centre in Hong Kong.

Yau TK, Choi CW, Sze H, Soong IS, Lee AW. Yau TK, et al. Hong Kong Med J. 2009 Apr;15(2):94-9. Hong Kong Med J. 2009. PMID: 19342734 Free article.

10

Surveillance mammography after breast conservation therapy in Hong Kong: effectiveness and feasibility of risk-adapted approach.

Yau TK, Sze H, Soong IS, Wong W, Chan K, Chang A, Lau KY, Lee A. Yau TK, et al. Breast. 2008 Apr;17(2):132-7. doi: 10.1016/j.breast.2007.08.001. Epub 2007 Oct 1. Breast. 2008. PMID: 17905584

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page